Biomarker technology roundup: from discovery to clinical applications, a broad set of tools is required to translate from the lab to the clinic.
Biomarkers are being utilized throughout the drug discovery and development process to understand fundamental biological processes and relationships. Specific biomarkers for disease states, prognosis, and response to therapy have been applied to screening tissues and serum, and serve as new tools in the development of therapeutics, to segment the population for specific treatments. The use of specific biomarkers to screen subjects to determine clinical trial eligibility, and for early toxicology studies, holds the potential to decrease drug failure rates in the later phases of the clinical trial process. Traditional research tools have been employed to study the genes, proteins, and metabolites of interest. In addition, new technologies and permutations of existing technologies have been developed particularly for investigation in the preclinical and clinical phases of drug development. More importantly, the transition of a compound from preclinical to clinical is aided by technologies that span both process segments. Identification of biomarkers that can be studied throughout the development process requires technologies that are both feasible and cost-effective for large patient populations.
Scaros
Olivia
O
Beachhead Consulting, Madison, CT 06443, USA.
Fisler
Richard
R
D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic; D023281:Genomics; D006801:Humans; D007753:Laboratories; D040901:Proteomics; D013672:Technology / Q000379:methods*
D015415:Biomarkers